Please turn JavaScript on
Homepage
TrendingMy newsFind FeedsDelivery settingsPlansMy earnings
HelpBlog
Log in
Find more feeds

Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals.

Is this your feed? Claim it!

Publisher:  Unclaimed!
Message frequency:  1.33 / day

Message History

SGLT2 Inhibitors in the GLP-1 Era: Why Dual Therapy Matters

As GLP-1 receptor agonists dominate headlines and prescribing trends, many clinicians wonder whether older therapies are losing relevance. However, SGLT2 inhibitors remain foundational in type 2 diabetes care. More importantly, evidence now supports the use of SGLT2 inhibitors and GLP-1 combination therapy in patients at high cardiovascular and renal risk. So instead of choos...


Read full story
Diabetic Retinopathy in 2026: AI Screening and Early Detection Updates

In 2026, diabetic retinopathy screening is entering a new era driven by artificial intelligence, tele-retinal imaging, and smarter integration into primary care workflows. Despite improved glucose monitoring and widespread use of CGM systems, diabetic retinopathy remains a leading cause of preventable blindness in adults with diabetes. So how can clinicians close the gap betw...


Read full story
Once-Weekly Basal Insulin: Does Simplicity Improve Adherence?

The arrival of a once-weekly basal insulin option marks one of the most meaningful advances in insulin therapy in decades. For years, daily basal injections have been the standard of care for people with type 1 and type 2 diabetes. However, many patients struggle with adherence, missed doses, and therapeutic inertia. So, does reducing injections from 365 per year to just 52 t...


Read full story
GLP-1s and Immune Modulation: Exploring Anti-Inflammatory Potential

Inflammation sits at the heart of cardiometabolic disease. While GLP-1 receptor agonists are best known for improving glycemic control and supporting weight loss, emerging research suggests their role may extend further. Could the anti-inflammatory effects of GLP-1 therapies help explain some of the cardiovascular benefits observed in large outcome trials?

Recent studi...


Read full story
GLP-1s and Autonomic Function: Understanding Heart Rate Changes in Clinical Practice

Changes in resting heart rate with GLP-1 receptor agonists have become an important topic in diabetes and cardiometabolic care. As glucagon-like peptide-1 receptor agonists such as semaglutide, liraglutide, and dulaglutide gain widespread use, clinicians often notice a modest rise in resting heart rate. Should this increase raise concern, especially in patients with cardiovas...


Read full story